Carmat - False start
Carmat published its H1 23 results. Revenues were impacted by supply issues resulting in production ramping-up slower than initially expected. The good news is that these issues have now been solved with a return to normal production levels over the summer. Around 20 Aeson prostheses are currently in inventory. Eligible patients have been identified in active centers and it is a matter of time before they get implanted. All parameters now point towards a significant rebound in H2 23. Management guides for EUR 4-6m revenues to be generated in H2 23. Short-term focus is of course on financing since theCarmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.